Literature DB >> 32460355

Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation.

Nianzhu Zhang1, Ming Li1, Xing Xu2, Yingshu Zhang1, Yancheng Liu2, Meng Zhao2, Peng Li2, Jun Chen3, Tomohiko Fukuda4, Jianguo Gu4, Xun Jin2, Wenzhe Li1.   

Abstract

As an immune checkpoint, programmed cell death 1 (PD-1) and its ligand (PD-L1) pathway plays a crucial role in CD8+ cytotoxic T lymphocytes (CTL) activation and provides antitumor responses. The N-glycans of PD-1 and PD-L1 are highly core fucosylated, which are solely catalyzed by the core fucosyltransferase (Fut8). However, the precise biological mechanisms underlying effects of core fucosylation of PD-1 and PD-L1 on CTL activation have not been fully understood. In this study, we found that core fucosylation was significantly upregulated in lung adenocarcinoma. Compared to those of Fut8+/+ OT-I mice, the lung adenocarcinoma formation induced by urethane was markedly reduced in Fut8-/- OT-I mice. De-core fucosylation of PD-1 compromised its expression on Fut8-/- CTL, resulted in enhanced Fut8-/- CTL activation and cytotoxicity, leading to more efficient tumor eradication. Indeed, loss of core fucosylation significantly enhanced the PD-1 ubiquitination and in turn led to the degradation of PD-1 in the proteasome. Our current work indicates that inhibition of core fucosylation is a unique strategy to reduce PD-1 expression for the antilung adenocarcinoma immune therapy in the future.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  CTL activation; Core fucosylation; Lung adenocarcinoma; Programmed cell death 1 (PD-1); Ubiquitination

Year:  2020        PMID: 32460355     DOI: 10.1002/eji.202048543

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma.

Authors:  Livia Rosa-Fernandes; Sueli Mieko Oba-Shinjo; Janaina Macedo-da-Silva; Suely Kazue Nagahashi Marie; Giuseppe Palmisano
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Analysis of the correlation of the expression level of hypoxia-inducible factor-1α with the glycosylation of oral squamous cell carcinoma.

Authors:  Xiaoliang Xu; Hui Liu; Ran Wu; Weiwen Zuo; Tiantao Wang; Dong Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.

Authors:  Xiaoming Dai; Yang Gao; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-04-05       Impact factor: 17.012

Review 4.  FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer.

Authors:  Kayla Bastian; Emma Scott; David J Elliott; Jennifer Munkley
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

5.  Lactobacillus spp. create a protective micro-ecological environment through regulating the core fucosylation of vaginal epithelial cells against cervical cancer.

Authors:  Qingjie Fan; Yuanhang Wu; Mechou Li; Fan An; Lulu Yao; Meixian Wang; Xiuying Wang; Jieli Yuan; Kui Jiang; Wenzhe Li; Ming Li
Journal:  Cell Death Dis       Date:  2021-11-20       Impact factor: 8.469

Review 6.  Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity.

Authors:  Yuhan Sun; Xueying Li; Tiantong Wang; Wenzhe Li
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 7.  Glycosylation of Immune Receptors in Cancer.

Authors:  Ruoxuan Sun; Alyssa Min Jung Kim; Seung-Oe Lim
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

Review 8.  FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.

Authors:  Chengcheng Liao; Jiaxing An; Suqin Yi; Zhangxue Tan; Hui Wang; Hao Li; Xiaoyan Guan; Jianguo Liu; Qian Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 9.  Fucosylation in Urological Cancers.

Authors:  Kazutoshi Fujita; Koji Hatano; Mamoru Hashimoto; Eisuke Tomiyama; Eiji Miyoshi; Norio Nonomura; Hirotsugu Uemura
Journal:  Int J Mol Sci       Date:  2021-12-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.